When comparing the weight of xenografts from sorafeinib treated and rhGRP78/sorafenib treated mice, we found that the mean weight in rhGRP78/sorafenib treated mice was significantly higher than that in sorafenib treated mice (rhGRP78/sorafenib versus sorafenib: 0.83 ± 0.45 g versus 0.43 ± 0.32 g), indicating that secreted GRP78 decreased the sensitivity of HCC cells to sorafenib in vivo (Figure 3A, 3B). This evidence concerns the gene HSPA5 and hepatocellular carcinoma.